Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Tivicay Launch Returns ViiV To HIV Spotlight And Growth

Executive Summary

The launch of Tivicay, a once-daily integrase inhibitor, will be the driving force behind the HIV specialist’s return to growth, anticipated in 2014, according to CEO Dominique Limet.

You may also be interested in...

ViiV’s Visibility Grows And Pressure Mounts For What Comes Next

GlaxoSmithKline’s HIV-focused business unit is growing leaps and bounds, while the company’s other pharmaceutical sales slump. ViiV CEO Dominique Limet talked in an interview about the increased pressure success brings and how ViiV intends to keep delivering.

ViiV IPO Plans Ditched By GSK; New Plan Is To Retain Value

The British health care company has decided not to spin out a minority stake in its fast-growing HIV joint venture, in part because of feedback from investors against the idea.

GSK Reveals Big Changes As 2015 Growth Prospects Fizzle

GlaxoSmithKline’s all important asthma drug, Advair, has taken a hit and the impact is bleeding out to the rest of the business. As GSK braces for a challenging 2015, the company announced a £1 billion cost savings program and plans to explore an IPO for its HIV subsidiary ViiV Healthcare.

Related Content


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts